RxDoctor Payments Data

Lauren Bruehl, OD

Optometrist · Crystal, MNNPI 1083106314

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (53.0%), travel and lodging and entertainment — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Biotissue Holdings Inc. at 55.6% of the total. 2025 is the largest year on record at $1,428, more than ten times the $41 reported in 2019. Among optometrist clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,472in general payments, 2019–2025

Across 49 payments — averaging $50.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$1K
  • Alcon$329
  • Johnson & Johnson Vision Care, Inc.$278
  • Coopervision Inc.$255
  • Optos, Inc.$70
  • AbbVie$50
  • plus $116 from 5 others

What the payments were for

  • Travel & lodging$1,07243%
  • Food & beverage$1,31053%
  • Gifts$191%
  • Entertainment$703%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,472 in reported general payments places this provider in the 90th percentile of 826 optometrist providers in Minnesota.

See all optometrist providers in Minnesota

Medicare billing

Part B allowed, 2024
$30,710
Medicare patients
116
Services billed
2,204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast24$43,077
RestasisCyclosporine33$40,171
Restasis MultidoseCyclosporine11$16,965
Cyclosporine21$10,669
Latanoprost91$1,551
Timolol Maleate44$672
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat17$519
Prednisolone Acetate13$428
Dorzolamide Hcl15$319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Restasis Multidose$50$57,13544 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 826 optometrist providers in Minnesota.

Other optometrist in Crystal

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →